v3.22.2.2
Revenue Recognition (Tables)
 12 Months Ended
Jun. 30, 2022
Disaggregation of Revenue [Line Items]  
Disaggregation of Revenue
The following tables reflect net revenue for the fiscal years ended June 30, 2022, 2021, and 2020 by type of activity and reporting segment (in millions):
Fiscal Year Ended June 30, 2022BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$607 $1,081 $403 $— $2,091 
Development services1,942 165 247 — 2,354 
Clinical supply services— — — 400 400 
Total$2,549 $1,246 $650 $400 $4,845 
Inter-segment revenue elimination(17)
Combined net revenue$4,828 
Fiscal Year Ended June 30, 2021BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$533 $877 $455 $— $1,865 
Development services1,395 135 231 — 1,761 
Clinical supply services— — — 391 391 
Total$1,928 $1,012 $686 $391 $4,017 
Inter-segment revenue elimination(19)
Combined net revenue$3,998 
Revenue Recognition and Deferred Revenue [Abstract]  
Contractual Liabilities The contract liabilities balances (current and non-current) as of June 30, 2022 and June 30, 2021 were as follows:
(Dollars in millions)
Balance at June 30, 2021$321 
Balance at June 30, 2022$194 
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:$(272)
geographical [Member]  
Disaggregation of Revenue [Line Items]  
Disaggregation of Revenue
The following table reflects net revenue by the location where the goods were made or the service performed:
(Dollars in millions)Fiscal Year Ended 
June 30, 2022		Fiscal Year Ended 
June 30, 2021		Fiscal Year Ended 
June 30, 2020
United States$3,110 $2,462 $1,822 
Europe1,506 1,343 976 
Other 327 288 376 
Elimination of revenue attributable to multiple locations(115)(95)(80)
Total$4,828 $3,998 $3,094